The FDA & NIH Building “Critical Bridge” to Treatments
Today, the LA Times & Bloomberg both reported on a recent development at both the National Institutes of Health and the Food and Drug Administration.
The NIH and the FDA are collaborating to build a “critical bridge” between biomedical research and new medical products. This collaboration will promote the development of testing and other tools that FDA regulators need in order to assess drugs and other products coming from fields such as genomics, nanotechnology and stem cell therapy. This news should be of interest to people who care about rare diseases for which there are no established testing protocols and should be monitored for its progress.
The NIH-FDA collaboration includes the formation of a six-member council of top scientists from both agencies to make sure that the latest science is incorporated into the regulatory review process. The NIH and FDA also will make at total of $6.75 million in grants for regulatory science research over a three-year period.
As we learn more about this collaboration we’ll inform you about what this means for research for all diseases.
Original Press Release: NIH and FDA Announce Collaborative Initiative to Fast-track Innovations to the Public: Partnership Combines Strengths to Speed New Treatments to Patients